Octreotide Acetate (Page 4 of 5)

Drug Abuse and Dependence

There is no indication that octreotide acetate has potential for drug abuse or dependence. Octreotide acetate levels in the central nervous system are negligible, even after doses up to 30,000 mcg.

DOSAGE AND ADMINISTRATION

Octreotide Acetate Injection may be administered subcutaneously or intravenously. Subcutaneous injection is the usual route of administration of Octreotide Acetate Injection for control of symptoms. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Multiple subcutaneous injections at the same site within short periods of time should be avoided. Sites should be rotated in a systematic manner.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulates and/or discoloration are observed. Proper sterile technique should be used in the preparation of parenteral admixtures to minimize the possibility of microbial contamination. Octreotide Acetate Injection is not compatible in Total Parenteral Nutrition (TPN) solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.

Octreotide Acetate Injection is stable in sterile isotonic saline solutions or sterile solutions of dextrose 5% in water for 24 hours. It may be diluted in volumes of 50 to 200 mL and infused intravenously over 15 to 30 minutes or administered by IV push over 3 minutes. In emergency situations (e.g., carcinoid crisis), it may be given by rapid bolus.

The initial dosage is usually 50 mcg administered twice or 3 times daily. Upward dose titration is frequently required. Dosage information for patients with specific tumors follows.

Acromegaly

Dosage may be initiated at 50 mcg 3 times a day. Beginning with this low dose may permit adaptation to adverse gastrointestinal effects for patients who will require higher doses. Insulin growth factor-1 (IGF-1; somatomedin C) levels every 2 weeks can be used to guide titration. Alternatively, multiple growth hormone (GH) levels at 0 to 8 hours after Octreotide Acetate Injection administration permit more rapid titration of dose. The goal is to achieve GH levels less than 5 ng/mL or IGF-1 (somatomedin C) levels less than 1.9 unit/mL in males and less than 2.2 unit/mL in females. The dose most commonly found to be effective is 100 mcg 3 times a day, but some patients require up to 500 mcg 3 times a day for maximum effectiveness. Doses greater than 300 mcg/day seldom result in additional biochemical benefit, and if an increase in dose fails to provide additional benefit, the dose should be reduced. IGF-1 (somatomedin C) or GH levels should be reevaluated at 6-month intervals.

Octreotide Acetate Injection should be withdrawn yearly for approximately 4 weeks from patients who have received irradiation to assess disease activity. If GH or IGF-1 (somatomedin C) levels increase and signs and symptoms recur, Octreotide Acetate Injection therapy may be resumed.

Carcinoid Tumors

The suggested daily dosage of Octreotide Acetate Injection during the first 2 weeks of therapy ranges from 100 to 600 mcg/day in 2 to 4 divided doses (mean daily dosage is 300 mcg). In the clinical studies, the median daily maintenance dosage was approximately 450 mcg, but clinical and biochemical benefits were obtained in some patients with as little as 50 mcg, while others required doses up to 1500 mcg/day. However, experience with doses above 750 mcg/day is limited.

VIPomas

Daily dosages of 200 to 300 mcg in 2 to 4 divided doses are recommended during the initial 2 weeks of therapy (range, 150 to 750 mcg) to control symptoms of the disease. On an individual basis, dosage may be adjusted to achieve a therapeutic response, but usually doses above 450 mcg/day are not required.

HOW SUPPLIED

Octreotide Acetate Injection is available in 1 mL single-dose vials and 5 mL multiple dose vials as follows:

NDC Number Octreotide Acetate Injection Vial/Package Size

0703-3301-04

50 mcg/mL

1 mL single-dose vial 25 per shelf tray

0703-3311-04

100 mcg/mL

1 mL single-dose vial 25 per shelf tray

0703-3321-04

500 mcg/mL

1 mL single-dose vial 25 per shelf tray

0703-3333-01

200 mcg/mL

5 mL multiple dose vial packaged individually

0703-3343-01

1000 mcg/mL

5 mL multiple dose vial packaged individually

Storage

For prolonged storage, Octreotide Acetate Injection single-dose vials and multiple dose vials should be stored at refrigerated temperatures 2°C to 8°C (36°F to 46°F) and protected from light. At room temperature (20°C to 30°C or 70°F to 86°F), Octreotide Acetate is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Single-dose vials should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.


Teva Pharmaceuticals USA, Inc. North Wales, PA 19454

Rev. G 9/2021

Package/Label Display Panel

image
(click image for full-size original)

Octreotide Acetate Injection 50 mcg/mL, 25 x 1 mL Single Dose Vial Tray Label Text

NDC 0703-3301-04 Rx only

Octreotide

Acetate Injection

50 mcg/mL

For Subcutaneous Injection

1 mL Single Dose Vial

25 Vials

Package/Label Display Panel

image
(click image for full-size original)

Octreotide Acetate Injection 100 mcg/mL, 25 x 1 mL Single Dose Vial Tray Label Text

NDC 0703-3311-04 Rx only

Octreotide

Acetate Injection

100 mcg/mL

For Subcutaneous Injection

1 mL Single Dose Vial

25 Vials

Package/Label Display Panel

image
(click image for full-size original)

Octreotide Acetate Injection 500 mcg/mL, 25 x 1 mL Single Dose Vial Tray Label Text

NDC 0703-3321-04 Rx only

Octreotide

Acetate Injection

500 mcg/mL

For Subcutaneous Injection

1 mL Single Dose Vial

25 Vials

Package/Label Display Panel

image
(click image for full-size original)

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.